SCHEMBL2652332

SCHEMBL2652332

CON(C)C(=O)c1cnc2ccccc2c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MGAM O43451 1/20 0.58
CFTR P13569 1/20 0.57
KDM4E B2RXH2 3/20 0.50
KMT2A Q03164 2/20 0.50
SMN1; SMN2 Q16637 2/20 0.50
CYP1A2 P05177 2/20 0.47
MEN1 O00255 1/20 0.47
MAPT P10636 1/20 0.47
CYP3A4 P08684 1/20 0.47
RAB9A P51151 2/20 0.46
NPC1 O15118 1/20 0.46
TRPM8 Q7Z2W7 1/20 0.45
MAP4K4 O95819 1/20 0.45
CSNK1G2 P78368 1/20 0.45
CLK4 Q9HAZ1 1/20 0.45
MKNK2 Q9HBH9 1/20 0.45
MAP4K5 Q9Y4K4 1/20 0.45
ALOX15 P16050 1/20 0.44
HTT P42858 1/20 0.44
BCAT1 P54687 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL529806 0.84 MGAM (0.65) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL20838250 0.82 HPGDS (0.46) CFTRTRPM8
SCHEMBL7600387 0.82 HPGDS (0.46) CFTRKMT2AMEN1
SCHEMBL2652683 0.82 HPGDS (0.67)
SCHEMBL13566 0.82 MALT1 (0.43) MGAMCFTRKMT2AMEN1RAB9A
SCHEMBL20023715 0.82 TRPM8 (0.41) MGAMCFTRMAPTTRPM8ALOX15
SCHEMBL31494490 0.82 HPGDS (0.46) CFTRTRPM8
SCHEMBL361516 0.81 ALOX15 (0.65) KMT2ASMN1; SMN2MEN1MAPTCYP3A4
SCHEMBL29050112 0.81 MGAM (0.69) MGAMCFTRKDM4EKMT2ASMN1; SMN2
SCHEMBL3401011 0.79 MGAM (0.58) MGAMCFTRKDM4EKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-109996546-A P2X3And/or P2X2/3Compounds and methods 阿沙纳生物科学公司 2019-07-09 CN disclosed
US-20140205537-A1 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2014-07-24 US disclosed
WO-2012178015-A2 LRRK2 INHIBITORS ZENOBIA THERAPEUTICS, INC. (US) 2012-12-27 WO disclosed
EP-1773330-B1 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK SHARP & DOHME (US) 2010-05-26 EP disclosed
US-7625938-B2 Substituted pyrazoles, compositions containing such compounds and methods of use MERCK & CO., INC. (US) 2009-12-01 US disclosed
EP-1773330-A4 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO INC (US) 2009-01-21 EP disclosed
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use MERCK & CO., INC. (US) 2008-05-08 US disclosed
EP-1773330-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE Merck & Co., Inc. (US) 2007-04-18 EP disclosed
WO-2006014618-A2 SUBSTITUTED PYRAZOLES, COMPOSITIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE MERCK & CO., INC. (US) 2006-02-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080108620-A1 Substituted Pyrazoles, Compositions Containing such Compounds and Methods of Use GLP1R, GCGR, GPR119 MGAM 1437/4885CFTR 532/4885KDM4E 3476/4885
US-20140205537-A1 LRRK2 INHIBITORS LRRK2, PARK7, MAP2 MGAM 4176/4885CFTR 4359/4885KDM4E 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.